Payne and colleagues indicated that a significant number of adolescent and young adult women are still not being given the information they desire regarding fertility preservation and therefore are not making fully informed treatment decisions.
The FDA granted accelerated approval to naxitamab-gqgk (Danyelza) in combination with GM-CSF for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
A study found that radiation therapy to treat childhood abdominal and pelvic cancers potentially caused body composition abnormalities and worse cardiometabolic health for adult survivors compared to the general public.
This study is intended to “investigate how chemotherapy disrupts sensory processing, memory, and attention in children; where in the brain the damage is occurring; and whether there is a biomarker that can identify those who are most vulnerable.”
This study found that abdominal or pelvic radiotherapy was associated with body composition changes that can adversely influence metabolic outcomes and performance status in survivors of abdominal or pelvic tumors.
Study findings suggested that survivors with severe hearing loss are at a significantly increased risk for neurocognitive deficits, independent of what type of therapy they receive.
A complete response letter was issued to Fennec Pharmaceuticals regarding the new drug application for a unique formulation of sodium thiosulfate (Pedmark).
Jennifer M. Yeh, PhD, spoke about study findings which indicated that instituting annual breast cancer screening with MRI at ages 25 to 30 years may reduce breast cancer mortality by 50% or more in survivors of childhood cancer.
These findings suggested that instituting annual breast cancer screening with MRI earlier may reduce breast cancer mortality by at least 50% in survivors of childhood cancer.
These results indicated the necessity for providers to address the concerns of AYAs with cancer, including those of a spiritual nature.